Federal Circuit Denies Rehearing In Dispute Over Biologics, Patents

(October 19, 2015, 10:34 AM EDT) -- WASHINGTON, D.C. — Competing motions for en banc rehearing of a July 2015 ruling by the Federal Circuit U.S. Court of Appeals in a dispute over the Biologics Price Competition and Innovation Act (BPCIA) were denied by the Federal Circuit on Oct. 16 (Amgen Inc. et al. v. Sandoz Inc. et al., No. 15-1499, Fed. Cir.).

(Order available. Document #16-151102-003R.)

According to the Federal Circuit “the petitions for rehearing were first referred to the panel that heard the appeal, and thereafter, to the circuit judges who...
To view the full article, register now.